20:15 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from its NVP025 program led to a greater survival rate in a mouse model of lethal mitochondrial myopathy compared with...
21:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
23:00 , Jan 4, 2018 |  BC Extra  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
01:38 , Jan 3, 2018 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury the...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
17:57 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Patient sample, rat and mouse studies suggest inhibiting CYPA could help treat ALS. Levels of CYPA were higher in CSF from sporadic ALS patients, a mouse model of familial ALS or...
22:35 , Dec 1, 2016 |  BC Innovations  |  Product R&D

De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders. The move...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA, CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections. In silico...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...
07:00 , Oct 21, 2016 |  BC Extra  |  Company News

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV. The exclusive, worldwide rights to NVP018 were obtained...